ArticleVaccine2017
Re-assessing the total burden of norovirus circulating in the United Kingdom population.
Article in Vaccine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Estimating wastewater concentrations of norovirus and rotavirus from global data on community-level infection prevalence and viral shedding.Journal of water and health · 2026Article
- Near-source wastewater surveillance of SARS-CoV-2, norovirus, influenza virus and RSV across five different sites in the UK.PLOS global public health · 2025Article
- Conformational Flexibility in Capsids Encoded by theViruses · 2024Review
- Predicting Norovirus in England Using Existing and Emerging Syndromic Data: Infodemiology Study.Journal of medical Internet research · 2023Article
- Norovirus attribution study: Detection of norovirus from the commercial food preparation environment in outbreak and non-outbreak premises.Journal of applied microbiology · 2022Article
- Article
- Article
- Complete genome characterization of human noroviruses allows comparison of minor alleles during acute and chronic infections.Access microbiology · 2021Article
- Estimating Disability-Adjusted Life Years (DALYs) in Community Cases of Norovirus in England.Viruses · 2019Article
- Norovirus strain types found within the second infectious intestinal diseases (IID2) study an analysis of norovirus circulating in the community.BMC infectious diseases · 2019Article
- Estimating the burden of care home gastroenteritis outbreaks in England, 2014-2016.BMC infectious diseases · 2019Article
- Estimating the Hospital Burden of Norovirus-Associated Gastroenteritis in England and Its Opportunity Costs for Nonadmitted Patients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018Article
- Estimating the Burden of Medically Attended Norovirus Gastroenteritis: Modeling Linked Primary Care and Hospitalization Datasets.The Journal of infectious diseases · 2017Article
- Methods for ascertaining norovirus disease burdens.Human vaccines & immunotherapeutics · 2017Article
- An Ontology to Improve Transparency in Case Definition and Increase Case Finding of Infectious Intestinal Disease: Database Study in English General Practice.JMIR medical informatics · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The second Infectious Intestinal Diseases study (IID2) estimated the incidence of norovirus in the UK at 47/1000 population (three million cases annually). Clinically significant norovirus was defined using a cycle threshold (ct) value of <30; a more stringent cut-off than used in diagnostic laboratories. The low infectious dose of norovirus means asymptomatic individuals potentially contribute to ongoing transmission. Using a less stringent but diagnostically relevant threshold increases the estimation of the population burden of norovirus infection by around 26% to 59/1000 person years (95% CI 52.32-64.98), equating to 3.7 million norovirus infections annually (3.3-4.1 million). With possible vaccines on the horizon for norovirus, having a good estimate of the total burden of norovirus infection, as well as symptomatic disease will be useful in helping to guide vaccination policy when candidate vaccines become available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.